企業を読み込み中
Keep exploring
The themes Caris Life Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.6BA+
EXELExelixis, Inc.$16.8BA+
JAZZJazz Pharmaceuticals plc$15.5BA
TECHBIO-Techne Corp$11.4BA+
HALOHalozyme Therapeutics, Inc.$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
どうやって稼いでいるか
- Molecular profiling services97%
- Pharma research and development services4%
売上構成比はsix months ended June 30, 2026の推計であり、提出された報告書の数字ではありません。
競合
- RHHBYFoundation Medicine (a Roche subsidiary)
- TEMTempus AIC
- 規模
- $13.1B
- 利益率
- -12.5%
- GHGuardant HealthB
- 規模
- $20.5B
- 利益率
- -37.9%
- NTRANateraB
- 規模
- $46.3B
- 利益率
- -5.7%
- GRALGRAILD
- 規模
- $5.2B
- 利益率
- -243.8%
- PSNLPersonalisD
- 規模
- $1.7B
- 利益率
- -147.7%
何を売っているか6
MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.
さらに3件を表示
Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.
誰が買っているか4
- Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
- Government and commercial health insurers pay for some patient tests when they cover the test and its use.
- Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
- Academic cancer centers and researchers use Caris data and collaborate on cancer research.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
- 2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
- 3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
- 4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.
うまくいかなくなる可能性
- 1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
- 2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
- 3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.
Caris Life Sciences, Inc.について
Caris analyzes DNA and RNA from cancer tissue and blood to find molecular features that may help doctors choose treatments. Its tests examine the whole exome—the protein-coding parts of DNA—or the whole transcriptome, and the company uses artificial intelligence (AI) and machine learning (ML) to interpret results. Caris also provides data and research services to drug companies and uses patient samples and data to investigate potential cancer drug targets.
- 本社
- Irving, Texas
- 設立
- 2008
- 上場市場
- Nasdaq
- 決算期
- December 31
Caris Life Sciences, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
